Clinical Cancer Research, Vol 2, Issue 9 1481-1487, Copyright © 1996 by American Association for Cancer Research

ARTICLES

Cyclophosphamide and 4-Hydroxycyclophosphamide/aldophosphamide kinetics in patients receiving high-dose cyclophosphamide chemotherapy

LW Anderson, TL Chen, OM Colvin, LB Grochow, JM Collins, MJ Kennedy and JM Strong
Division of Clinical Pharmacology Research, U.S. Food and Drug Administration, Center for Drug Evaluation and Research, OTR, Laurel, Maryland 20708, USA.

Using a recently developed gas chromatography and mass spectrometry method to determine whole-blood cyclophosphamide (CP) and 4-hydroxycyclophosphamide/aldophosphamide (4-HO-CP/AP) concentrations, we investigated their pharmacokinetics in women receiving CP therapy. Patients (n = 18) received one or two courses of CP: (a) a 90-min i.v. infusion (4 g/m2) followed by a 96-h i.v. infusion (6 g/m2) in combination with high-dose thiotepa; or (b) a 96-h i.v. infusion (6 g/m2) in combination with high-dose thiotepa. Whole-blood exposures to CP [area under the whole blood concentration versus time curve (AUCCP)] and 4-HO-CP/AP (AUC4HOCP) between courses 1 and 2 were compared after normalization to dose (g/m2). A nonproportional increase was observed for the AUCCP between the first course [1112 micrometer. h/g/m2 +/- 14% coefficient of variation (CV)] and the second course (1579 micrometer . h/g/m2 +/- 28% CV) (P < 0.001). In contrast, the AUC4HOCP (27 micrometer . h/g/m2 +/- 25% CV) determined for the first course was 29% higher than the AUC4HOCP (21 micrometer . h/g/m2 +/- 26% CV) for the second course (P < 0.01). The interpatient whole-blood exposures to both CP and 4-HO-CP/AP were remarkably consistent in this patient population with percent CVs ranging from 14 to 28%. Because thiotepa (800 mg/m2) was administered simultaneously with CP during the second course of treatment, possible inhibition of CP metabolism by thiotepa was investigated using human liver microsomes in vitro. IC50 values determined for inhibition of CP metabolism in three individual liver donors ranged from 1.0 to 40 micrometer. However, the clinical relevance of this observation has not been established.

This article has been cited by other articles:

				E. Bodo, D. J. Tobin, Y. Kamenisch, T. Biro, M. Berneburg, W. Funk, and R. Paus Dissecting the Impact of Chemotherapy on the Human Hair Follicle: A Pragmatic in Vitro Assay for Studying the Pathogenesis and Potential Management of Hair Follicle Dystrophy Am. J. Pathol., October 1, 2007; 171(4): 1153 - 1167. [Abstract] [Full Text] [PDF]

				S. M. Yule, L. Price, A. D. McMahon, A. D. J. Pearson, and A. V. Boddy Cyclophosphamide Metabolism in Children with Non-Hodgkin's Lymphoma Clin. Cancer Res., January 15, 2004; 10(2): 455 - 460. [Abstract] [Full Text] [PDF]

				J. M. Rae, N. V. Soukhova, D. A. Flockhart, and Z. Desta Triethylenethiophosphoramide Is a Specific Inhibitor of Cytochrome P450 2B6: Implications for Cyclophosphamide Metabolism Drug Metab. Dispos., May 1, 2002; 30(5): 525 - 530. [Abstract] [Full Text] [PDF]

				W. P. Petros, G. Broadwater, D. Berry, R. B. Jones, J. J. Vredenburgh, C. J. Gilbert, J. P. Gibbs, O. M. Colvin, and W. P. Peters Association of High-dose Cyclophosphamide, Cisplatin, and Carmustine Pharmacokinetics with Survival, Toxicity, and Dosing Weight in Patients with Primary Breast Cancer Clin. Cancer Res., March 1, 2002; 8(3): 698 - 705. [Abstract] [Full Text] [PDF]

				S. Rodenhuis The Status of High-Dose Chemotherapy in Breast Cancer Oncologist, October 1, 2000; 5(5): 369 - 375. [Abstract] [Full Text]

				W. P. Petros and O. M. Colvin Metabolic Jeopardy with High-Dose Cyclophosphamide?--Not So Fast Clin. Cancer Res., April 1, 1999; 5(4): 723 - 724. [Full Text] [PDF]

				T.-L. Chen, M. J. Kennedy, L. W. Anderson, S. B. Kiraly, K. C. Black, O. M. Colvin, and L. B. Grochow Nonlinear Pharmacokinetics of Cyclophosphamide and 4-Hydroxycyclophosphamide/Aldophosphamide in Patients with Metastatic Breast Cancer Receiving High-dose Chemotherapy Followed by Autologous Bone Marrow Transplantation Drug Metab. Dispos., May 1, 1997; 25(5): 544 - 551. [Abstract] [Full Text]